Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (171-180 of 703) with videos related to

Pageof 71
Sort By:
Cell Death & Disease|November 9, 2013
AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanomaW Hu, L Jin, C C Jiang, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2021
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancersDirk Schadendorf, Caroline Robert, Reinhard Dummer, et al.
The British Journal of Surgery|July 17, 2019
External validation of a prognostic model to predict survival of patients with sentinel node-negative melanomaN A Ipenburg, O E Nieweg, T Ahmed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2014
Reply to M. Perier-Muzet et alLisa Zimmer, Lauren E Haydu, Alexander M Menzies, et al.
Frontiers in Oncology|June 13, 2020
Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF InhibitorsArturas Ziemys, Michelle Kim, Alexander M Menzies, et al.
Biomolecules|June 26, 2025
Pre-Amplification of Cell-Free DNA: Balancing Amplification Errors with Enhanced SensitivityWei Yen Chan, Ashleigh Stewart, Russell J Diefenbach, et al.
Future Oncology (London, England)|September 1, 2022
KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanomaGeorgina V Long, Pier Francesco Ferrucci, Adnan Khattak, et al.
Cancers|October 14, 2022
Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response BiomarkersElena Shklovskaya, Bernadette Pedersen, Ashleigh Stewart, et al.
Cancers|April 30, 2021
Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C InhibitionJohn J Park, Russell J Diefenbach, Natalie Byrne, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2023
Adjuvant therapy for stage II melanoma: the need for further studiesRebecca Lee, Mario Mandala, Georgina V Long, et al.
Pageof 71

Showing results (171-180 of 703) with videos related to

Sort By:
Pageof 71
Cell Death & Disease|November 9, 2013
AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanomaW Hu, L Jin, C C Jiang, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2021
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancersDirk Schadendorf, Caroline Robert, Reinhard Dummer, et al.
The British Journal of Surgery|July 17, 2019
External validation of a prognostic model to predict survival of patients with sentinel node-negative melanomaN A Ipenburg, O E Nieweg, T Ahmed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2014
Reply to M. Perier-Muzet et alLisa Zimmer, Lauren E Haydu, Alexander M Menzies, et al.
Frontiers in Oncology|June 13, 2020
Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF InhibitorsArturas Ziemys, Michelle Kim, Alexander M Menzies, et al.
Biomolecules|June 26, 2025
Pre-Amplification of Cell-Free DNA: Balancing Amplification Errors with Enhanced SensitivityWei Yen Chan, Ashleigh Stewart, Russell J Diefenbach, et al.
Future Oncology (London, England)|September 1, 2022
KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanomaGeorgina V Long, Pier Francesco Ferrucci, Adnan Khattak, et al.
Cancers|October 14, 2022
Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response BiomarkersElena Shklovskaya, Bernadette Pedersen, Ashleigh Stewart, et al.
Cancers|April 30, 2021
Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C InhibitionJohn J Park, Russell J Diefenbach, Natalie Byrne, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2023
Adjuvant therapy for stage II melanoma: the need for further studiesRebecca Lee, Mario Mandala, Georgina V Long, et al.
Pageof 71